Price modelling and price sensitivity
Knowing how a change in brand price premium can impact sales is crucial. We use state-of-the-art economic evaluation techniques to build the most appropriate pricing strategy based on clinical trial evidence for new and existing pharmaceutical products. With this information, clients are better equipped and are able to make informed decisions on how to optimise their product portfolio ensuring they achieve maximum sales volumes and return on investment.
We assist development of long-term strategies to better manage product performance. IMS P&MA consultants can provide ways and means to sustain post-launch product value that covers the spectrum of price defence from new market entrants through to mature products and generics.